Revenue growth of 42% (excluding SCC and ID Genetics) was primarily driven by double-digit volume increases in core DecisionDx-Melanoma and TissueCypher tests. DecisionDx-Melanoma achieved record monthly test reports in March 2026, supported by new SEER-linked data demonstrating improved risk prediction over traditional AJCC staging. TissueCypher volume grew 58% year-over-year, though management noted that the franchise has reached a penetration level where first-quarter seasonality in GI procedures i ...